| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD55; CR; DAF; Complement decay-accelerating factor; CD55 |
| Entrez GeneID | 1604 |
| WB Predicted band size | Calculated MW: 41 kDa; Observed MW: 55-80 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human CD55 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CD55抗体的3篇代表性文献及其摘要概括：
---
1. **"Structure and function of the decay-accelerating factor (CD55)"**
*作者：Nicholas, M.K. & Lublin, D.M.*
该文献系统综述了CD55的分子结构及其在补体调控中的作用，重点探讨其通过抑制C3/C5转化酶形成保护宿主细胞免受补体攻击的机制。
2. **"Targeting CD55 enhances antibody-mediated complement-dependent cytotoxicity against cancer cells"**
*作者：Kessel, S. et al.*
研究证明，使用抗CD55抗体可阻断肿瘤细胞表面的补体抑制信号，显著增强抗体药物(如利妥昔单抗)在淋巴瘤模型中的补体依赖性细胞毒性(CDC)疗效。
3. **"CD55 as a therapeutic target in tumor migration and resistance to therapy"**
*作者：Günthert, U. et al.*
文章发现CD55在多种实体瘤中高表达，并通过调控细胞迁移信号通路促进转移。使用特异性抗体阻断CD55可抑制肿瘤侵袭性并提高化疗敏感性。
---
(注：以上文献标题和作者为示例性虚构，建议通过PubMed或Google Scholar检索真实文献。)
CD55. also known as decay-accelerating factor (DAF), is a membrane-bound glycoprotein that regulates the complement system, a critical component of innate immunity. Primarily expressed on the surface of blood cells, endothelial cells, and epithelial cells, CD55 protects host cells from unintended complement-mediated damage by accelerating the decay of C3 and C5 convertases, key enzymes in the complement activation cascade. This inhibitory function prevents excessive complement activation, which could otherwise lead to tissue injury and autoimmune disorders.
Structurally, CD55 consists of four short consensus repeat (SCR) domains, an O-glycosylated stalk, and a glycosylphosphatidylinositol (GPI) anchor that tethers it to the cell membrane. Its expression can be both constitutively present and dynamically upregulated during inflammation. Deficiencies or dysregulation of CD55 are linked to diseases such as paroxysmal nocturnal hemoglobinuria (PNH), where impaired CD55 expression results in complement-mediated erythrocyte lysis, and certain autoimmune conditions like rheumatoid arthritis.
CD55 antibodies are essential tools for studying its expression, distribution, and functional roles. Therapeutic applications include targeting CD55 to modulate complement activity in autoimmune diseases or cancers, where tumors may overexpress CD55 to evade immune surveillance. Additionally, CD55 serves as a receptor for some pathogens (e.g., enteroviruses), making it a potential target for antiviral therapies. Research continues to explore its dual role in immunity and disease pathogenesis.
×
